|
Jul 16
|
Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer
|
|
Jul 15
|
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
|
|
Jul 15
|
Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical
|
|
Jun 17
|
Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans
|
|
Feb 13
|
Invitation to Presentation of Cantargia’s Year-End Report 2024
|
|
Oct 11
|
Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study
|
|
Oct 10
|
Cantargia’s Strong Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab Published in Clinical Cancer Research
|
|
May 23
|
Annual General Meeting in Cantargia AB (publ)
|
|
Feb 7
|
Invitation to Presentation of Cantargia’s Year-End Report 2023 on February 22 at 3.00 p.m. CET
|
|
Jan 9
|
Cantargia Reports Phase I Clinical Progress in the CAN10 Project
|
|
Nov 30
|
New Number of Shares and Votes in Cantargia
|